Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBIN: Encorafenib/Binimetinib Induction in BRAF+ Melanoma
NCT03235245Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2018
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of encorafenib, binimetinib in melanoma, sponsored by European Organisation for Research and Treatment of Cancer. Started Oct 2018; status: active, not recruiting.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03235245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03235245.